Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 gene doubles risk of ovarian cancer:

This article was originally published in Clinica

Executive Summary

Variations in the COX-2 gene can double or even treble a woman's risk of ovarian cancer. In a 727-patient study, Portuguese researchers found that a specific allele of the gene doubled the risk of the disease, and trebled the likelihood in women under 53. Since other COX-2 influenced diseases can be treated with non-steroidal anti-inflammatory drugs (NSAIDS), the finding raises the possibility of a theranostic test for the disease, said the researchers, based at the Portuguese Institute of Oncology in Porto. It is thought that NSAIDS, such as ibuprofen and aspirin, could be used to help prevent ovarian cancer in those who test positive. The results were presented at the conference of the European CanCer Organisation (ECCO) in Barcelona, Spain, from 23-27 September.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel